Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals, have received marketing approval for Relistor subcutaneous injection from the European Commission.
Subscribe to our email newsletter
Relistor is now approved in the 27 member states of the EU as well as Iceland, Norway, and Liechtenstein for the treatment of opioid-induced constipation (OIC) in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. Relistor is said to be the first approved treatment for OIC in the EU.
Commercial launch of Relistor in Europe will be rolled out on a country-by-country basis, with the first launch anticipated to occur later July 2008.
Paul Maddon, founder, CEO and chief science officer of Progenics, said: “Approval in Europe significantly extends the availability of Relistor for advanced illness patients receiving palliative care who experience opioid-induced constipation, a potentially debilitating side effect of opioid therapy.”